Epithalon (Epitalon) Dosage Guide: Protocols, Timing & How Much to Take (2026)

Epithalon (Epitalon) Dosage Guide: Protocols, Timing & How Much to Take (2026)

From Peptidepedia, the trusted peptide wiki.

Medical Advisory Board

Dosage Protocols

No FDA-approved dosing guidelines exist for Epithalon. The following information is derived from published research protocols and community reports:

Research Protocol Dosing:

Standard protocol: 5 to 10 mg per day via subcutaneous injection for 10 to 20 consecutive days

Cycling: Repeat once or twice per year, with 4 to 6 month intervals between cycles

Higher doses: Some community protocols report doses above 10 mg/day, though no published data supports increased efficacy beyond the standard range

Community Dosing Protocols:

Conservative: 5 mg subcutaneously once daily for 20 days, twice per year

Moderate: 10 mg subcutaneously once daily for 10 days, twice per year

Split dosing: 5 mg twice daily (morning and evening) for 10 days

Timing: Evening or bedtime administration is commonly recommended to align with natural melatonin rhythms, particularly for individuals using Epithalon with the intent of supporting circadian regulation. Epithalon is also reviewed in the [best peptides for sleep guide](/guides/best-peptides-for-sleep).

Cycling Rationale: The intermittent protocol, short treatment courses separated by months-long breaks, is based on the hypothesis that Epithalon triggers regulatory cascades that persist after the peptide itself is cleared, rather than requiring continuous receptor occupancy. This is consistent with the bioregulation framework that underpins Khavinson's research, though it has not been validated through pharmacokinetic studies in humans.

Frequently Asked Questions

Research protocols typically use 5 to 10 mg per day via subcutaneous injection for 10 to 20 consecutive days, repeated once or twice per year. No FDA-approved dosing guidelines exist, and optimal dosing in humans has not been established through rigorous clinical trials.

Research protocols typically administer Epithalon for 10 to 20 consecutive days per cycle, with cycles repeated every 4 to 6 months. Continuous long-term use has not been studied. The intermittent cycling approach is based on the hypothesis that the peptide resets regulatory pathways rather than requiring sustained exposure.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592.

Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240.

Anisimov VN, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202.

Anisimov VN, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7-10.

Khavinson VK, et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol. 2007;20(1):74-85.

Khavinson VK, et al. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Exp Gerontol. 2005;40(1-2):51-57.

Anisimov VN, et al. Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice. Bull Exp Biol Med. 2002;133(3):274-276.

Khavinson VK. Peptides and ageing. Neuro Endocrinol Lett. 2002;23(Suppl 3):11-144.

Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178.

Kossoy G, et al. Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa. Int J Mol Med. 2003;12(4):473-477.